Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Loomba, Rohit et al.·The lancet. Gastroenterology & hepatology·2023·
RPEP-071322023RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Published In:
The lancet. Gastroenterology & hepatology, 8(6), 511-522 (2023)
Database ID:
RPEP-07132

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-07132·https://rethinkpeptides.com/research/RPEP-07132

APA

Loomba, Rohit; Abdelmalek, Manal F; Armstrong, Matthew J; Jara, Maximilian; Kjær, Mette Skalshøi; Krarup, Niels; Lawitz, Eric; Ratziu, Vlad; Sanyal, Arun J; Schattenberg, Jörn M; Newsome, Philip N. (2023). Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.. The lancet. Gastroenterology & hepatology, 8(6), 511-522. https://doi.org/10.1016/S2468-1253(23)00068-7

MLA

Loomba, Rohit, et al. "Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.." The lancet. Gastroenterology & hepatology, 2023. https://doi.org/10.1016/S2468-1253(23)00068-7

RethinkPeptides

RethinkPeptides Research Database. "Semaglutide 2·4 mg once weekly in patients with non-alcoholi..." RPEP-07132. Retrieved from https://rethinkpeptides.com/research/loomba-2023-semaglutide-24-mg-once

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.